2024-11-23 - Analysis Report
## Intuitive Surgical Inc. (ISRG) Stock Analysis Report

**1. Performance Comparison & Divergence:**

Intuitive Surgical Inc. (ISRG) is a company that manufactures and sells the da Vinci surgical system, a robotic surgery system.

The cumulative return of ISRG is significantly higher than that of the S&P 500 (VOO).

| Metric                    | ISRG       | VOO        | Difference | Relative Divergence |
|-------------------------|-------------|-------------|-------------|----------------------|
| Cumulative Return (%)     | 341.38%     | 127.58%     | 213.80%     | 98.69%              |


The table below shows the Compound Annual Growth Rate (CAGR), Maximum Drawdown (MDD), Alpha, Beta, and Market Capitalization (Cap) for ISRG over various periods:

| Year       | CAGR     | MDD (%) | Alpha | Beta | Cap (B) |
|------------|----------|---------|-------|------|---------|
| 2015-2017  | 108.3%   | 12.5    | 69.9% | 0.8  | 43.3    |
| 2016-2018  | 162.5%   | 23.1    | 130.2%| 1.2  | 56.9    |
| 2017-2019  | 176.3%   | 23.1    | 124.6%| 1.4  | 70.2    |
| 2018-2020  | 118.0%   | 40.1    | 70.7% | 1.2  | 97.1    |
| 2019-2021  | 131.3%   | 40.1    | 31.3% | 1.2  | 128.0   |
| 2020-2022  | 33.3%    | 47.6    | 9.7%  | 1.2  | 94.5    |
| 2021-2023  | 26.5%    | 47.6    | -8.4% | 1.4  | 120.2   |
| 2022-2024  | 52.2%    | 47.0    | 22.1% | 1.3  | 196.1   |

ISRG consistently outperforms the S&P 500, as indicated by its high alpha values, although the outperformance has fluctuated over time.  The Beta values show varying degrees of sensitivity to market movements.


**2. Recent Price Movement:**

| Metric            | Value     |
|--------------------|-----------|
| Closing Price     | $547.87   |
| 5-Day MA          | $542.15   |
| 20-Day MA         | $526.79   |
| 60-Day MA         | $501.36   |

The stock price is currently trading above its 5, 20, and 60-day moving averages, suggesting upward momentum.


**3. Technical Indicators:**

* **RSI (79.53):**  Indicates the stock is in overbought territory, suggesting a potential pullback.
* **PPO (0.18):** A positive value suggests bullish momentum, but it's relatively low.
* **20-Day Relative Divergence (1.51):** Shows a recent increase in relative strength, confirming the upward trend.
* **Expected Return (2.31%):** This represents the expected excess return over the S&P 500 for long-term (2+ years) investment.  The high value implies a strong expectation of outperformance.

The last market price of 547.77 is close to the closing price, suggesting no significant intraday volatility.  There's no evidence of a rapid surge or plummet.


**4. Recent Financial Performance:**

| Date       | EPS      | Revenue ($B) |
|------------|----------|--------------|
| 2024-10-18 | $1.59    | $2.04        |
| 2024-07-19 | $1.48    | $2.01        |
| 2024-04-19 | $1.54    | $1.89        |
| 2023-10-20 | $1.18    | $1.74        |
| 2024-10-18 | $1.18    | $1.74        | *(Duplicate entry, likely an error)*


Revenue shows slight fluctuation but remains consistently strong, indicating sustained growth.  EPS also shows generally strong performance.  Further analysis would require comparison to analyst estimates and historical performance to determine if the latest results meet or exceed expectations.  The duplicate entry needs clarification.


**6. Financial Information:**

**1) Revenue and Profitability:**

| Quarter      | Revenue ($B) | Profit Margin (%) |
|--------------|---------------|--------------------|
| 2024-09-30  | $2.04         | 67.41              |
| 2024-06-30  | $2.01         | 68.30              |
| 2024-03-31  | $1.89         | 65.87              |
| 2023-12-31  | $1.93         | 66.24              |
| 2023-09-30  | $1.74         | 66.94              |

High and consistent profit margins demonstrate the company's strong financial health and pricing power.


**2) Capital and Profitability:**

| Quarter      | Equity ($B) | ROE (%) |
|--------------|---------------|---------|
| 2024-09-30  | $15.58        | 3.63    |
| 2024-06-30  | $14.71        | 3.58    |
| 2024-03-31  | $13.96        | 3.90    |
| 2023-12-31  | $13.31        | 4.56    |
| 2023-09-30  | $12.54        | 3.32    |

ROE is relatively stable, indicating consistent profitability relative to shareholder equity.


**7. News and Recent Issues:**

*(This section requires real-time data from sources like Shacknews, Finbold, and financial news outlets.  I cannot access real-time information.  This section would include analysis of recent earnings reports, analyst ratings, market outlook, and any significant news events impacting ISRG.)*


**8. Overall Analysis:**

ISRG exhibits strong long-term growth, significantly outperforming the S&P 500.  However, the RSI suggests it is currently overbought, hinting at a potential short-term correction.  Consistent revenue and profitability, alongside a positive long-term outlook, support its continued success.  Nevertheless, the overbought condition and the need for clarification on duplicate financial data warrant caution.  Further research into the recent news and analyst opinions (as detailed in section 7) is crucial for a complete assessment.


**9. Disclaimer:** This report is for informational purposes only and does not constitute financial advice.  Investing in the stock market involves risk, and past performance is not indicative of future results.  Conduct thorough research and consider consulting with a financial advisor before making any investment decisions.
